Asia vaccines market is estimated at $7bn in 2018 and is expected to grow at a CAGR of 8.8% during the first half of the forecast period. The Japanese vaccines market held 30% share of the Asian vaccines market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 178-page report you will receive 82 charts– all unavailable elsewhere.
The 178-page report provides clear detailed insight into the Asian vaccines market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Asia Vaccines Market revenue forecasts to 2029
• Asia Vaccines Market revenue forecasts to 2029 by Vaccine Technology: • Conjugate Vaccines • Inactivated and Subunit Vaccines • Live Attenuated Vaccines • Recombinant Vaccines • Toxoid Vaccines
• Asia Vaccines Market revenue forecasts to 2029 by Indication: • Influenza • Hepatitis • Polio • Meningococcal • DTP • Rotavirus • MMR • HPV • Others
Please note: The Asia Influenza Vaccines Market has been updated with a range of different economic case scenarios following the global COVID-19 pandemic.
• Asia Vaccines Market revenue forecasts to 2029 by Country: • Japan • China • India • Australia • South Korea • Vietnam • Philippines • Thailand • Indonesia • Rest of Asia
Further segmented by indication and vaccine technology.
• Profiles of the selected leading companies: • Astellas • AstraZeneca • CSL, Ltd. • Emergent BioSolutions, Inc. • GlaxoSmithKline • Johnson & Johnson • Merck • Mitsubishi Tanabe Pharma Corporation • Pfizer • Sanofi • Serum Institute of India Pvt. Ltd. • Sun Pharmaceuticals Industries, Ltd. • Takeda
• This report provides a Pipeline Analysis
• This report discusses factors that drive and restrain the market. This report also discusses trends and opportunities in the market.
• Key Questions Answered by this Report: • What is the current size of Asia vaccines market? How much will this market be worth from 2018 to 2029? • What are the main drivers and restraints that will shape Asia vaccines market over the next ten years? • What are the main segments within Asia vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for the Asian vaccines market? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2029? • Who are the leading companies and what are their activities, results, developments and prospects?
Visiongain’s study is intended for anyone requiring commercial analyses for Asia Vaccines Market. You find data, trends and predictions.
Buy our report today Asia Vaccines Market Forecast to 2029: Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1. Asia Vaccines Market Overview 1.2. Asia Vaccines Market Segmentation 1.3. Why You Should Read This Report 1.4. How This Report Delivers 1.5. Key Questions Answered by This Analytical Report 1.6. Who is This Report For? 1.7. Methodology 1.8. Frequently Asked Questions (FAQ) 1.9. Associated Visiongain Reports 1.10. About Visiongain
2. Introduction to Vaccines Market 2.1. What are Vaccines? 2.2. Diseases Vaccines Prevent 2.3. Drivers and Challenges for the Asia Vaccines Market 2.3.1. Drivers 2.3.1.1. Growing demand in Asian region 2.3.1.2. Rising geriatric population 2.3.1.3. Increasing Population 2.3.1.4. Growing Life Expectancy 2.3.2. Restraints 2.3.2.1. Funding difficult to sustain 2.4. Opportunities
3. Asia Vaccines Market 2019-2029 3.1. Asia Vaccines as a Share of the Global Vaccines Market 3.2. The Global Vaccines Market in 2018 3.2.1. Leading Companies in the Vaccines Market 3.3. Asia Vaccines Market in 2018 3.4. How Will Segmental Market Shares Change to 2029?
4. Asia Vaccines Market by Vaccine Technology 2018-2029 4.1. Leading Vaccine Technologies in 2018 4.2. Conjugate Vaccines 4.3. Inactivated and Subunit Vaccines 4.4. Live Attenuated Vaccines 4.5. Recombinant Vaccines 4.6. Toxoid Vaccines
5. Asia Vaccines Market by Indication 2018-2029 5.1. Leading Indications in 2018 5.2. Influenza 5.2.1 Asia Vaccines Market - Economic case scenarios following COVID-19 pandemic 5.3. Hepatitis 5.4. Polio 5.5. Meningococcal 5.6. DTP 5.7. Rotavirus 5.8. MMR 5.9. HPV
6. Asia Vaccines Market by Country 2018-2029 6.1. Leading Countries in 2018 6.2. Japan 6.2.1. Vaccines in Japan 6.2.2. Immunisation Program 6.2.3. Vaccine Production 6.2.4. Vaccine Regulation 6.3. China 6.3.1. Vaccines in China 6.3.2. Vaccine Production 6.3.3. Vaccine Regulations 6.4. India 6.4.1. Vaccination Schedule India 6.4.2. Immunisation Program 6.4.3. Vaccine Production 6.5. Australia 6.5.1. Vaccination Schedule Australia 6.5.2. Immunisation Program 6.5.3. Vaccine Regulation 6.6. South Korea 6.6.1. Vaccines in South Korea 6.6.2. Immunisation Program 6.6.3. South Korea Production 6.6.4. South Korea Regulation 6.7. Vietnam 6.7.1. Vaccines in Vietnam 6.7.2. Immunisation Program 6.7.3. Vietnam Production 6.7.4. Vietnam Regulations 6.8. Philippines 6.8.1. Vaccines in Philippines 6.8.2. Immunisation Program 6.8.3. Vaccine Production and Regulation 6.9. Thailand 6.9.1. Vaccines in Thailand 6.9.2. Immunisation Program 6.9.3. Thailand Production and Regulation 6.10. Indonesia 6.10.1. Vaccines in Indonesia 6.10.2. Immunisation Program
7. Company Profiles 7.1. Merck & Co., Inc. Overview 7.1.1. Merck Financial Outlook 7.1.2. Merck Product Portfolio 7.1.3. Merck Strategic Developments 7.2. Sanofi Overview 7.2.1. Sanofi Financial Outlook 7.2.2. Sanofi Product Portfolio 7.2.3. Sanofi Strategic Developments 7.3. Pfizer Overview 7.3.1. Pfizer Financial Outlook 7.3.2. Pfizer Product Portfolio 7.3.3. Pfizer Strategic Developments 7.4. GlaxoSmithKline PLC Overview 7.4.1. GlaxoSmithKline PLC Financial Outlook 7.4.2. GlaxoSmithKline PLC Product Portfolio 7.4.3. GlaxoSmithKline PLC Strategic Developments 7.5. Johnson & Johnson Overview 7.5.1. Johnson & Johnson Financial Outlook 7.5.2. Johnson & Johnson Product Portfolio 7.5.3. Johnson & Johnson Strategic Developments 7.6. AstraZeneca Overview 7.6.1. AstraZeneca Financial Outlook 7.6.2. AstraZeneca Product Portfolio 7.6.3. AstraZeneca Strategic Developments 7.7. Emergent BioSolutions, Inc. 7.7.1. Emergent BioSolutions Financial Outlook 7.7.2. Emergent BioSolutions Product Portfolio 7.7.3. Emergent BioSolutions Strategic Developments 7.8. CSL Ltd. Overview 7.8.1. CSL Ltd. Financial Outlook 7.8.2. CSL Ltd. Product Portfolio 7.8.3. CSL Ltd. Strategic Developments 7.9. Serum Institute of India Pvt. Ltd. Overview 7.9.1. Serum Institute of India Pvt. Ltd. Financial Outlook 7.9.2. Serum Institute of India Pvt. Ltd. Product Portfolio 7.9.3. Serum Institute of India Pvt. Ltd. Strategic Developments 7.10. Astellas Pharma Overview 7.10.1. Astellas Pharma Financial Outlook 7.10.2. Astellas Pharma Product Portfolio 7.10.3. Astellas Pharma Strategic Developments 7.11. Mitsubishi Tanabe Pharma Corporation Overview 7.11.1. Mitsubishi Tanabe Pharma Corporation Financial Outlook 7.11.2. Mitsubishi Tanabe Pharma Corporation Product Portfolio 7.11.3. Mitsubishi Tanabe Pharma Corporation Strategic Developments 7.12. Sun Pharmaceuticals Industries Ltd. Overview 7.12.1. Sun Pharmaceutical Industries Ltd. Financial Outlook 7.12.2. un Pharmaceutical Industries Ltd. Product Portfolio 7.12.3. Sun Pharmaceutical Industries Ltd. Strategic Developments 7.13. Takeda Pharmaceutical Company Limited Overview 7.13.1. Takeda Pharmaceutical Company Limited, Financial Outlook 7.13.2. Takeda Pharmaceutical Company Limited, Product Portfolio 7.13.3. Takeda Pharmaceutical Company Limited. Strategic Developments
8. Conclusions 8.1. Vaccines Market: Strong Growth Expected 8.2. Asia Vaccines Market in 2018 8.2.1. Current Leading Vaccine Technology Segments 8.2.2. Current Leading Indication Segments 8.2.3. Leading National and Regional Markets 8.3. Asia Vaccines Market Forecast 2018-2029 8.4. Pipeline Analysis 8.5. New Vaccine Opportunities
Appendices Glossary Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain report evaluation form
List of Tables Table 2.1 Vaccines R&D in Asia Table 3.1 Asia Vaccines Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 4.1 Asia Vaccines Market and Forecast by Vaccine Technology Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 4.2 Asia Conjugate Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 4.3 Asia Inactivated Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 4.4 Asia Live Attenuated Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 4.5 Asia Recombinant Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 4.6 Asia Toxoid Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.1 Asia Vaccines Market and Forecast by Indication Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.2 Asia Influenza Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.3 Asia Hepatitis Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.4 Asia Polio Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.5 Asia Meningococcal Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.6 Asia DTP Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.7 Asia Rotavirus Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.8 Asia MMR Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 5.9 Asia HPV Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.1 Asia Vaccines Market and Forecast, by Country Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.2 Japan Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.3 Japan Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.4 Japan Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.5 China Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.6 China Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.7 China Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.8 India Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.9 India Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.10 India Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.11 Australia Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.12 Australia Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.13 Australia Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.14 South Korea Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.15 South Korea Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.16 South Korea Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.17 Vietnam Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.18 Vietnam Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.19 Vietnam Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.20 Philippines Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.21 Philippines Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.22 Philippines Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.23 Thailand Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.24 Thailand Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.25 Thailand Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.26 Indonesia Vaccines Market and Forecast: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.27 Indonesia Vaccines Market and Forecast by Indication: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 6.28 Indonesia Vaccines Market and Forecast by Vaccine Technology: Revenues ($m), AGR (%) and CAGR (%), 2018-2029 Table 8.1 Pipeline Analysis: Vaccines Market Table 8.2 HIV Vaccine: Product Pipeline Table 8.3 Malaria Vaccine: Product Pipeline
List of Figures Figure 1.1 Asia Vaccines Market Segmentation Overview, 2018 Figure 2.1 History of Vaccine Development Figure 2.2 Drivers & Restraints: Asia Vaccines Market Figure 3.1 Global Vaccines Market Forecast: Revenues ($bn) and AGR (%), 2018-2029 Figure 3.2 Asia Vaccines Market Forecast: Revenues ($m) and AGR (%), 2018-2029 Figure 3.3 Asia Vaccines Market by Vaccine Technology: Market Shares (%), 2018 and 2029 Figure 3.4 Asia Vaccines Market by Indication: Market Shares (%), 2018 and 2029 Figure 3.5 Asia Vaccines Market by Country: Market Shares (%), 2018 and 2029 Figure 4.1 Asia Vaccines Market and Forecast: Revenues ($m) and AGR (%), 2018-2029 Figure 4.2 Asia Conjugate Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 4.3 Asia Inactivated Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 4.4 Asia Live Attenuated Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 4.5 Asia Recombinant Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 4.6 Asia Toxoid Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.1 Asia Vaccines Market and Forecast: Revenues ($m) and AGR (%), 2018-2029 Figure 5.2 Asia Influenza Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.3 Asia Hepatitis Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.4 Asia Polio Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.5 Asia Meningococcal Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.6 Asia DTP Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.7 Asia Rotavirus Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.8 Asia MMR Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 5.9 Asia HPV Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.1 Asia Vaccines Market and Forecast: Revenues ($m) and AGR (%), 2018-2029 Figure 6.2 Japan Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.3 China Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.4 India Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.5 Australia Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.6 South Korea Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.7 Vietnam Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.8 Philippines Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.9 Thailand Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 6.10 Indonesia Vaccines Market and Forecast: Revenues ($m), and AGR (%), 2018-2029 Figure 8.1 Asia Vaccines Market Forecast: Revenues ($m) by Vaccine Technology, 2018-2029
Afferent Pharmaceuticals Affinivax, Inc. Astellas Pharma AstraZeneca Bavarian Nordic BIKEN Co. Ltd Biological E. Limited Biomedical Advanced Research and Development Authority (BARDA) BioNTech Cancer Research UK Chiba University CSL, Ltd. Daiichi Sankyo Company, Ltd. Emergent Biosolutions, Inc. European Commission Ganymed Pharmaceuticals AG GlaxoSmithKline GlycoVaxyn AG HitGen Immunomic Therapeutics, Inc. Inovio Pharmaceuticals IOmet Janssen Johnson & Johnson MedImmune Merck & Co., Inc. Mitsubishi Tanabe Pharma Corporation Moderna Nanotherapeutics Osaka University Oswaldo Cruz Foundation PaxVax Pfizer Potenza Therapeutics, Inc. Protein Sciences Sanofi Seqirus Serum Institute of India Pvt. Ltd. Sun Pharmaceuticals Industries, Ltd. Takeda University of Oxford University of Tokyo Zydus Cadila
Download sample pages
Complete the form below to download your free sample pages for Asia Vaccines Market Forecast to 2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
Immuno-Oncology Clinical Trials market is valued at US$6,849.8 million in 2023 and is projected to grow at a CAGR of 11.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
